⌘K
Loading ticker…
As of 2026-08-24, CG Oncology, Inc. Common stock (CGON) has a 3-month relative strength percentile of 83 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 72. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.5%, relative volume 1.45×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
CGON is in a stage 2 uptrend, week 9. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 9.5% / 31.6%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
CGON is held by 29 ETFs as of May 2026. Top owner: SCHA at 0.09% weight, $20M notional. Top 3 carry $47M.
Held by 72 ETFs · $769M across latest filings · largest weight 3.35% (SBIO).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.09% | $20M | — |
| VTWO | 0.11% | $19M | — |
| VHTVanguard Health Care ETF | 0.04% | $8M | — |
| SBIO | 3.35% | $5M | +0.29 pp |
| CANC | 2.43% | $4M | +0.74 pp |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.21% |
| $3M |
| — |
| VFMO | 0.14% | $3M | +0.03 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.01% | $2M | — |
| ONEQ | 0.01% | $1M | — |
| ESML | 0.05% | $1M | −0.01 pp |
Showing 10 of 29 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CGON Jan avg: 10.15% median: 4.85% win: 100% σ: 13.37% n: 3 2024-01-26 → 2026-07-31 | CGON Feb avg: 6.32% median: 12.97% win: 67% σ: 17.95% n: 3 2024-01-26 → 2026-07-31 | CGON Mar avg: 2.66% median: -1.81% win: 33% σ: 10.91% n: 3 2024-01-26 → 2026-07-31 | CGON Apr avg: 0.06% median: -1.39% win: 33% σ: 9.31% n: 3 2024-01-26 → 2026-07-31 | CGON May avg: -10.17% median: -6.67% win: 0% σ: 7.64% n: 3 2024-01-26 → 2026-07-31 | CGON Jun avg: 4.15% median: 1.48% win: 67% σ: 8.89% n: 3 2024-01-26 → 2026-07-31 | CGON Jul avg: 2.83% median: 2.65% win: 100% σ: 2.73% n: 3 2024-01-26 → 2026-07-31 | CGON Aug avg: 5.54% median: 5.54% win: 100% σ: 7.14% n: 2 2024-01-26 → 2026-07-31 (current) | CGON Sep avg: 26.25% median: 26.25% win: 100% σ: 33.86% n: 2 2024-01-26 → 2026-07-31 | CGON Oct avg: 0.80% median: 0.80% win: 50% σ: 9.37% n: 2 2024-01-26 → 2026-07-31 | CGON Nov avg: 0.72% median: 0.72% win: 50% σ: 4.12% n: 2 2024-01-26 → 2026-07-31 | CGON Dec avg: -12.44% median: -12.44% win: 0% σ: 7.12% n: 2 2024-01-26 → 2026-07-31 |